点滴液市場：タイプ別、組成液別、エンドユーザー別-2025-2030年の世界予測

点滴液市場の2023年の市場規模は137億6,000万米ドルで、2024年には149億9,000万米ドルに達すると予測され、CAGR 9.13％で成長し、2030年には253億8,000万米ドルに達すると予測されています。

静脈注射液は医療において重要なコンポーネントであり、必須栄養素、薬剤、水分補給を血流に直接送り込む手段として機能します。この方法は、物質の迅速な吸収と輸送を保証し、治療効果を即座に促進します。輸液の必要性は、救急医療、手術、慢性疾患管理、水分補給療法など、クリティカルケア用途で特に顕著です。ヘルスケアのエコシステムの中で、最終用途の範囲は病院、外来手術センター、在宅ケアに及び、それぞれが信頼性の高い静脈内投与メカニズムを必要としています。主な成長促進要因としては、世界人口の高齢化、慢性・急性疾患の有病率の上昇、在宅ヘルスケアの採用増加などが挙げられます。電解質輸液やビタミン強化輸液の市場開拓などの技術進歩は、市場の拡大をさらに促進します。外来医療サービスの拡大や、患者固有のニーズに応じた正確な投与による個別化治療ソリューションに治療機会があります。しかし、感染リスク、厳しい規制枠組み、変動する原料価格などの課題が大きな阻害要因となっています。さらに、無菌の輸送・保管インフラが必要なため運用コストが上昇し、小規模メーカーの参入を制限しています。技術革新の余地がある分野としては、患者のバイタル監視や正確な流量を確保するためのセンサーを備えたスマート輸液システムの開発、環境への影響を低減するための環境に優しいパッケージングなどが挙げられます。市場関係者は、治療の効果を最適化し、患者のコンプライアンスを高めることができる、点滴治療の遠隔モニタリング用IoT（モノのインターネット）デバイスなどの技術統合への投資を検討すべきです。既存の障壁を克服し、市場のイノベーションをリードするためには、特に費用対効果が高く持続可能なソリューションの研究開発に注力し続けることが重要です。輸液ソリューションの市場は、臨床ニーズと新たなヘルスケア動向の双方に牽引され、依然としてダイナミックです。

市場力学：急速に進化する点滴液市場の主要市場インサイトを公開

点滴液市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 胃腸障害、がん、神経疾患などの慢性・急性疾患の発生率の増加
  • 点滴注射の規制承認の増加
  • 製品ポートフォリオを強化するためのメーカー間の戦略的提携の増加
• 市場抑制要因
  • 輸液の維持にかかるコストの高さ
• 市場機会
  • 新興経済諸国からの点滴液需要の増加
  • 患者の利便性を高める製品の改良と新たなイノベーション
  • 大腸がん患者へのビタミンC点滴静注の実施
• 市場の課題
  • 点滴の副作用

ポーターのファイブフォース：点滴液市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：点滴液市場における外部からの影響の把握

外部マクロ環境要因は、点滴液市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析点滴液市場における競合情勢の把握

点滴液市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス点滴液市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、点滴液市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨点滴液市場における成功への道筋を描く

点滴液市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胃腸障害、がん、神経疾患などの慢性疾患および急性疾患の発生率の増加
    • 静脈注射液の規制承認の増加
    • 製品ポートフォリオ強化に向けたメーカー間の戦略的提携の増加
  • 抑制要因
    • 流体のメンテナンスコストが高い
  • 機会
    • 新興経済諸国からの点滴液の需要増加
    • 患者の利便性を考慮した製品の改善と新たなイノベーション
    • 大腸がん患者に対するビタミンC点滴の実施
  • 課題
    • 点滴液の副作用
• 市場セグメンテーション分析
  • タイプ：栄養と代謝のニーズの高まりにより、完全静脈栄養の使用が拡大
  • エンドユーザー：幅広い患者のニーズに応えるために病院や診療所からの需要が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 点滴液市場：タイプ別

• 末梢静脈栄養
• 完全静脈栄養

第7章 点滴液市場作曲ソリューション

• 炭水化物
• デキストラン
• ヘパリンと微量元素
• 非経口脂質乳剤
• 単回投与アミノ酸溶液
• ビタミンとミネラル

第8章 点滴液市場：エンドユーザー別

• 外来手術センター
• 病院・クリニック
• 長期介護施設
• 専門クリニック

第9章 南北アメリカの点滴液市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の点滴液市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの点滴液市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ヒクマ、COMBOGESIC IVの米国での発売を発表
  • サンジヴァニ・パランテラル・リミテッドとHALがIV製剤とIVセットの製造で提携
  • CTMUHBとバクスターが提携し、より安全な点滴輸液投与を実現
• 戦略分析と提言

企業一覧

• Ajinomoto Co., Inc.
• Amanta Healthcare Ltd.
• Anhui Medipharm Co. Ltd
• Axa Parenterals Ltd
• B. Braun Melsungen AG
• Baxter International Inc
• Becton, Dickinson and Company
• Enzymes Pharmaceuticals
• Eurolife Healthcare Pvt. Ltd.
• Fresenius SE & Co. KGaA
• Grifols, S.A.
• ICU Medical, Inc.
• JW Life Science Corporation
• Lxir Medilabs Pvt. Ltd.
• Nymak Pharma Ltd.
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Salius Pharma Private Limited
• Schwitz Biotech
• Sichuan Kelun Pharmaceutical Co., Ltd.
• Soxa Formulations & Research Pvt. Ltd.
• Terumo Corporation
• Trumac Healthcare
• Varni Corporation
• Vifor Pharma Management Ltd.

LIST OF FIGURES

• FIGURE 1. INTRAVENOUS SOLUTIONS MARKET RESEARCH PROCESS
• FIGURE 2. INTRAVENOUS SOLUTIONS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. INTRAVENOUS SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. INTRAVENOUS SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INTRAVENOUS SOLUTIONS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INTRAVENOUS SOLUTIONS MARKET DYNAMICS
• TABLE 7. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY PERIPHERAL PARENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TOTAL PARENTERAL NUTRITION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY CARBOHYDRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY DEXTRAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY HEPARIN & TRACE ELEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY PARENTERAL LIPID EMULSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY SINGLE DOSE AMINO ACID SOLUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INTRAVENOUS SOLUTIONS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM INTRAVENOUS SOLUTIONS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM INTRAVENOUS SOLUTIONS MARKET SIZE, BY COMPOSITION SOLUTION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM INTRAVENOUS SOLUTIONS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 149. INTRAVENOUS SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. INTRAVENOUS SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2023

The Intravenous Solutions Market was valued at USD 13.76 billion in 2023, expected to reach USD 14.99 billion in 2024, and is projected to grow at a CAGR of 9.13%, to USD 25.38 billion by 2030.

Intravenous (IV) solutions are a critical component in medical care, serving as a means for delivering essential nutrients, medications, and hydration directly into the bloodstream. This method ensures rapid absorption and transport of substances, facilitating immediate therapeutic effects. The necessity of IV solutions is particularly prominent in emergency medicine, surgeries, chronic illness management, and hydration therapy, among other critical care applications. Within the healthcare ecosystem, the end-use scope extends to hospitals, ambulatory surgical centers, and home care settings, each requiring reliable IV delivery mechanisms. Key growth drivers include an aging global population, rising prevalence of chronic and acute illnesses, and the increasing adoption of home healthcare. Technological advancements, such as the development of electrolyte-infused and vitamin-enriched solutions, further enhance market expansion. Opportunities lie in expanding outpatient care services and individualized treatment solutions with accurate dosing according to patients' specific needs. However, challenges such as the risk of infections, stringent regulatory frameworks, and fluctuating raw material prices pose significant restraints. Additionally, the necessity for sterile transport and storage infrastructure elevates operational costs, limiting entry for small-scale manufacturers. Areas ripe for innovation include the development of smart infusion systems equipped with sensors for monitoring patient vitals and ensuring accurate flow rates, as well as eco-friendly packaging to reduce environmental impact. Market players should consider investing in technological integrations such as Internet of Things (IoT) devices for remote monitoring of intravenous therapies, which can optimize treatment efficacy and enhance patient compliance. Maintaining focus on research and development, particularly around cost-effective and sustainable solutions, will be crucial in overcoming existing barriers and leading market innovations. The market for IV solutions remains dynamic, driven by both clinical needs and emerging healthcare trends.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intravenous Solutions Market

The Intravenous Solutions Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in the Incidence of Chronic and Acute Diseases such as Gastrointestinal Disorder, Cancer, and Neurological Diseases
  • Increasing Regulatory Approvals for Intravenous Solution Injections
  • Rise in Strategic Collaborations Between Manufacturers to Enhance their Product Portfolio
• Market Restraints
  • High Cost of Maintenance of Fluids
• Market Opportunities
  • Increase in Demand for Intravenous Solutions from Developing Economies
  • Improvements and New Innovations in the Products for Patient Convenience
  • Implementation of Vitamin C Intravenous for Patients with Colorectal Cancer
• Market Challenges
  • Side Effects of Intravenous Fluids

Porter's Five Forces: A Strategic Tool for Navigating the Intravenous Solutions Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intravenous Solutions Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Intravenous Solutions Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intravenous Solutions Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Intravenous Solutions Market

A detailed market share analysis in the Intravenous Solutions Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intravenous Solutions Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intravenous Solutions Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Intravenous Solutions Market

A strategic analysis of the Intravenous Solutions Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Intravenous Solutions Market, highlighting leading vendors and their innovative profiles. These include Ajinomoto Co., Inc., Amanta Healthcare Ltd., Anhui Medipharm Co. Ltd, Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Enzymes Pharmaceuticals, Eurolife Healthcare Pvt. Ltd., Fresenius SE & Co. KGaA, Grifols, S.A., ICU Medical, Inc., JW Life Science Corporation, Lxir Medilabs Pvt. Ltd., Nymak Pharma Ltd., Otsuka Holdings Co., Ltd., Pfizer Inc., Salius Pharma Private Limited, Schwitz Biotech, Sichuan Kelun Pharmaceutical Co., Ltd., Soxa Formulations & Research Pvt. Ltd., Terumo Corporation, Trumac Healthcare, Varni Corporation, and Vifor Pharma Management Ltd..

Market Segmentation & Coverage

This research report categorizes the Intravenous Solutions Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Peripheral Parenteral Nutrition and Total Parenteral Nutrition.
• Based on Composition Solution, market is studied across Carbohydrates, Dextran, Heparin & Trace Element, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, and Vitamins & Minerals.
• Based on End-users, market is studied across Ambulatory Surgical Centers, Hospitals & Clinics, Long-term Care Facilities, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the Incidence of Chronic and Acute Diseases such as Gastrointestinal Disorder, Cancer, and Neurological Diseases
    • 5.1.1.2. Increasing Regulatory Approvals for Intravenous Solution Injections
    • 5.1.1.3. Rise in Strategic Collaborations Between Manufacturers to Enhance their Product Portfolio
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Maintenance of Fluids
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in Demand for Intravenous Solutions from Developing Economies
    • 5.1.3.2. Improvements and New Innovations in the Products for Patient Convenience
    • 5.1.3.3. Implementation of Vitamin C Intravenous for Patients with Colorectal Cancer
  • 5.1.4. Challenges
    • 5.1.4.1. Side Effects of Intravenous Fluids
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Widening use of total parenteral nutrition owing to rising nutritional and metabolic needs
  • 5.2.2. End-Users: Rising demand from hospitals & clinics to cater to a broad spectrum of patient needs
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Intravenous Solutions Market, by Type

• 6.1. Introduction
• 6.2. Peripheral Parenteral Nutrition
• 6.3. Total Parenteral Nutrition

7. Intravenous Solutions Market, by Composition Solution

• 7.1. Introduction
• 7.2. Carbohydrates
• 7.3. Dextran
• 7.4. Heparin & Trace Element
• 7.5. Parenteral Lipid Emulsion
• 7.6. Single Dose Amino Acid Solution
• 7.7. Vitamins & Minerals

8. Intravenous Solutions Market, by End-users

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals & Clinics
• 8.4. Long-term Care Facilities
• 8.5. Specialty Clinics

9. Americas Intravenous Solutions Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Intravenous Solutions Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Intravenous Solutions Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Hikma announces US launch of COMBOGESIC IV
  • 12.3.2. Sanjivani Paranteral Limited and HAL collaborate to manufacture IV formulations and IV Sets
  • 12.3.3. CTMUHB and Baxter partner to implement safer IV fluid administration
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Ajinomoto Co., Inc.
• 2. Amanta Healthcare Ltd.
• 3. Anhui Medipharm Co. Ltd
• 4. Axa Parenterals Ltd
• 5. B. Braun Melsungen AG
• 6. Baxter International Inc
• 7. Becton, Dickinson and Company
• 8. Enzymes Pharmaceuticals
• 9. Eurolife Healthcare Pvt. Ltd.
• 10. Fresenius SE & Co. KGaA
• 11. Grifols, S.A.
• 12. ICU Medical, Inc.
• 13. JW Life Science Corporation
• 14. Lxir Medilabs Pvt. Ltd.
• 15. Nymak Pharma Ltd.
• 16. Otsuka Holdings Co., Ltd.
• 17. Pfizer Inc.
• 18. Salius Pharma Private Limited
• 19. Schwitz Biotech
• 20. Sichuan Kelun Pharmaceutical Co., Ltd.
• 21. Soxa Formulations & Research Pvt. Ltd.
• 22. Terumo Corporation
• 23. Trumac Healthcare
• 24. Varni Corporation
• 25. Vifor Pharma Management Ltd.